Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Autoři	BÁRTŮ KENDALL Michaela NĚMEJCOVÁ Kristýna MICHÁLKOVÁ Romana BUI Quang Hiep DROZENOVÁ Jana FABIAN Pavel FADARE Oluwole HAUSNEROVÁ Jitka LACO Jan MATĚJ Radoslav MÉHES Gábor ŠAFANDA Adam SINGH Naveena ŠKAPA Petr ŠPŮRKOVÁ Zuzana STOLNICU Simona ŠVAJDLER Marián LAX Sigurd F MCCLUGGAGE W Glenn DUNDR Pavel
Rok publikování	2024
Druh	Článek v odborném periodiku
Časopis / Zdroj	International Journal of Gynecological Pathology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://journals.lww.com/intjgynpathology/Abstract/9900/Neuroendocrine_Marker_Expression_in_Primary.90.aspx
Doi	http://dx.doi.org/10.1097/PGP.0000000000000962
Klíčová slova	INSM1; Synaptophysin; Chromogranin; Immunohistochemistry; Ovarian Tumors
Popis	Expression of neuroendocrine (NE) markers in primary ovarian non-NE epithelial tumors has rarely been evaluated. The aim of our study was to evaluate the expression of the most widely used NE markers in these neoplasms and to determine any prognostic significance of NE marker expression. The cohort consisted of 551 primary ovarian tumors, including serous borderline tumors, low-grade serous carcinomas, high-grade serous carcinomas (HGSC), clear cell carcinomas, endometroid carcinomas, mucinous borderline tumors, and mucinous carcinomas. Immunohistochemical analysis was performed using antibodies against INSM1, synaptophysin, chromogranin, and CD56 on tissue microarray. Positivity for INSM1, synaptophysin, chromogranin, and CD56 was most frequently observed in mucinous tumors (48.7%, 26.0%, 41.5%, and 100%, respectively). The positivity for these NE markers was mostly restricted to nonmucinous elements distributed throughout the tumor. The mucinous borderline tumor and mucinous carcinomas groups had similar proportions of positivity (mucinous borderline tumor: 53%, mucinous carcinomas: 39%). In the other tumor types, except for HGSC, there was only focal expression (5%–10%) or negativity for NE markers. HGSC showed high CD56 expression (in 26% of cases). Survival analysis was only performed for CD56 in HGSC as this was the only group with sufficient positive cases, and it showed no prognostic significance. Except for mucinous tumors, expression of NE markers in non-NE ovarian epithelial tumors is low. CD56 expression in HGSC occurs frequently but is without diagnostic or prognostic value.